Literature DB >> 12565977

The challenges and achievements involved in implementing Quality of Life research in cancer clinical trials.

A Bottomley1, V Vanvoorden, H Flechtner, P Therasse.   

Abstract

Over the last decade, Quality of Life (QOL) research has become an important aspect of cancer clinical trials. A dramatically increasing number of published studies, both randomised and non-randomised, report QOL outcomes. There is increasing evidence that QOL results impact on both future research and treatment decisions for clinicians. The rising number of studies with QOL components is mirrored within the European Organization for Research and Treatment of Cancer (EORTC), one of the largest cancer clinical trial organisations in Europe. Clinical trial groups have frequently reported on the difficulties and challenges of implementing QOL research. In the following paper, we therefore examine past experience in EORTC QOL studies, with a focus on the challenges presented and the improved approaches that are being implemented to obtain more meaningful outcomes.

Entities:  

Mesh:

Year:  2003        PMID: 12565977     DOI: 10.1016/s0959-8049(02)00729-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  18 in total

Review 1.  [Comorbidity oriented oncology - an overview].

Authors:  Ralph Simanek; Michael Wuensch; Roland Edlinger; Bernhard Hammerl-Ferrari; Ludwig Kramer; Klaus Geissler
Journal:  Wien Klin Wochenschr       Date:  2010-04       Impact factor: 1.704

2.  Neurocognitive and sociodemographic functioning of glioblastoma long-term survivors.

Authors:  Birgit Flechl; Michael Ackerl; Cornelia Sax; Karin Dieckmann; Richard Crevenna; Alexander Gaiger; Georg Widhalm; Matthias Preusser; Christine Marosi
Journal:  J Neurooncol       Date:  2012-05-29       Impact factor: 4.130

3.  Clarifying quality of life assessment: do theoretical models capture the underlying cognitive processes?

Authors:  Elsbeth F Bloem; Florence J van Zuuren; Margot A Koeneman; Bruce D Rapkin; Mechteld R M Visser; Caro C E Koning; Mirjam A G Sprangers
Journal:  Qual Life Res       Date:  2008-08-14       Impact factor: 4.147

4.  Joint modeling of longitudinal health-related quality of life data and survival.

Authors:  Divine E Ediebah; Francisca Galindo-Garre; Bernard M J Uitdehaag; Jolie Ringash; Jaap C Reijneveld; Linda Dirven; Efstathios Zikos; Corneel Coens; Martin J van den Bent; Andrew Bottomley; Martin J B Taphoorn
Journal:  Qual Life Res       Date:  2014-10-14       Impact factor: 4.147

Review 5.  Patient-reported outcomes as end points and outcome indicators in solid tumours.

Authors:  Angeles A Secord; Robert L Coleman; Laura J Havrilesky; Amy P Abernethy; Gregory P Samsa; David Cella
Journal:  Nat Rev Clin Oncol       Date:  2015-03-10       Impact factor: 66.675

6.  Quality of life in patients with Graves ophthalmopathy.

Authors:  R Patrick Yeatts
Journal:  Trans Am Ophthalmol Soc       Date:  2005

Review 7.  Quality of life in gastric cancer.

Authors:  Ad-A Kaptein; Satoshi Morita; Junichi Sakamoto
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

8.  Health-related quality of life in women previously treated for early-stage breast cancer.

Authors:  Wayne A Bardwell; Jacqueline M Major; Cheryl L Rock; Vicky A Newman; Cynthia A Thomson; Janice A Chilton; Joel E Dimsdale; John P Pierce
Journal:  Psychooncology       Date:  2004-09       Impact factor: 3.894

Review 9.  Reporting and interpretation of SF-36 outcomes in randomised trials: systematic review.

Authors:  Despina G Contopoulos-Ioannidis; Anastasia Karvouni; Ioanna Kouri; John P A Ioannidis
Journal:  BMJ       Date:  2009-01-12

10.  A 'short walk' is longer before radiotherapy than afterwards: a qualitative study questioning the baseline and follow-up design.

Authors:  Elsbeth F Taminiau-Bloem; Florence J van Zuuren; Margot A Koeneman; Bruce D Rapkin; Mechteld R M Visser; Caro C E Koning; Mirjam A G Sprangers
Journal:  Health Qual Life Outcomes       Date:  2010-07-16       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.